Fidelity Investments
GPCR icon

Fidelity Investments’s Structure Therapeutics GPCR Stock Holding History

Fidelity Investments’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419M Sell
7,810,306
-593,143
-7% -$26.2M 0.02% 623
2026
Q1 		$405M Sell
8,403,449
-308,802
-4% -$21.1M 0.02% 586
2025
Q4 		$606M Buy
8,712,251
+3,461,883
+66% +$141M 0.03% 441
2025
Q3 		$147M Buy
5,250,368
+335,403
+7% +$6.68M 0.01% 996
2025
Q2 		$102M Sell
4,914,965
-968,742
-16% -$21.3M 0.01% 1110
2025
Q1 		$102M Sell
5,883,707
-195,039
-3% -$4.78M 0.01% 1090
2024
Q4 		$165M Sell
6,078,746
-49,698
-0.8% -$1.76M 0.01% 898
2024
Q3 		$269M Buy
6,128,444
+383,635
+7% +$14.8M 0.02% 711
2024
Q2 		$226M Buy
5,744,809
+2,796,045
+95% +$115M 0.01% 744
2024
Q1 		$126M Sell
2,948,764
-1,085,820
-27% -$45.8M 0.01% 966
2023
Q4 		$164M Buy
4,034,584
+2,444,249
+154% +$140M 0.01% 826
2023
Q3 		$80.2M Buy
1,590,335
+352,600
+28% +$11.4M 0.01% 1064
2023
Q2 		$51.5M Sell
1,237,735
-11,691
-0.9% -$328K ﹤0.01% 1265
2023
Q1 		$29.7M Buy
+1,249,426
New +$29.4M ﹤0.01% 1449

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments's GPCR Position: Q2 2026 in Review

Fidelity Investments reduced its Structure Therapeutics (GPCR) stake by 7.1% in Q2 2026, selling an estimated $26.2M and leaving 7,810,306 shares worth $419M. The position accounts for 0.02% of the portfolio, ranked #623.

Fidelity Investments first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $606M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Fidelity Investments held 7,810,306 shares of Structure Therapeutics worth $419M as of Q2 2026.
  • Fidelity Investments sold 593,143 Structure Therapeutics shares in Q2 2026, an estimated $26.2M.
  • Structure Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #623 holding.
  • Fidelity Investments first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Fidelity Investments's Structure Therapeutics position peaked at $606M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.